EMA rejects claims of undue industry influence on data disclosure policy
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has dismissed suggestions that the 2013 appointment of a new head of legal services with an industry background had a significant influence on the development of its draft policy on clinical trial data disclosure. It has also sharply rejected the idea that it does not pay sufficient attention to the interests of patients.